Effects of Bariatric Surgery on HDL Cholesterol

Idoia Genua1, Analia Ramos1, Francisca Caimari1

  • 1Endocrinology and Nutrition Service, Hospital de la Santa Creu i Sant Pau, Sant Antoni Maria Claret, 167, 08025, Barcelona, Spain.

Obesity Surgery
|January 17, 2020
PubMed

Insights

Bariatric surgery significantly improves high-density lipoprotein cholesterol (HDLc) levels, peaking two years post-operation. Pre-surgery HDLc and surgical method predict the extent of this beneficial increase.

Area of Science:

  • Cardiology
  • Metabolic Surgery
  • Lipid Metabolism

Background:

  • Low high-density lipoprotein cholesterol (HDLc) is a risk factor for coronary heart disease.
  • Bariatric surgery is known to increase HDLc, but the timeline and predictors are not fully understood.

Purpose of the Study:

  • To analyze the temporal changes in HDLc concentrations following bariatric surgery.
  • To identify predictors of HDLc level increases after bariatric procedures.

Main Methods:

  • Retrospective observational study of 185 patients undergoing bariatric surgery.
  • Exclusion of patients with revisional surgery or those on fibrates.
  • Analysis of medical records from January 2007 to March 2015.

Main Results:

  • HDLc levels initially decreased at 3 months post-surgery but began to rise thereafter.
  • Maximum HDLc increase (26.2%) was observed 2 years after surgery.
  • Preoperative HDLc levels and surgical type (sleeve gastrectomy vs. gastric bypass) predicted the magnitude of HDLc increase.

Conclusions:

  • Bariatric surgery positively impacts HDLc levels.
  • The peak increase in postoperative HDLc occurs 2 years after the procedure.
  • Preoperative HDLc and surgical approach are key predictors of HDLc improvement post-bariatric surgery.
Abstract

Related Concept Videos

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
190
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.3K
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
280